Commentary on "Prognosis according to the timing of recurrence in breast cancer" (Ann Surg Treat Res 2023;104:1-9).

Autor: Hlauschek D; ABCSG (Austrian Breast and Colorectal Cancer Study Group), Vienna, Austria., Gnant M; ABCSG (Austrian Breast and Colorectal Cancer Study Group), Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Jazyk: angličtina
Zdroj: Annals of surgical treatment and research [Ann Surg Treat Res] 2024 Apr; Vol. 106 (4), pp. 237-238. Date of Electronic Publication: 2024 Mar 29.
DOI: 10.4174/astr.2024.106.4.237
Abstrakt: Competing Interests: Conflict of Interest: Michael Gnant reports personal fees/travel support from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini-Stemline, MSD, Novartis, Pierre Fabre, Sandoz, Veracyte; an immediate family member is employed by Sandoz. No other potential conflicts of interest relevant to this article was reported.
Databáze: MEDLINE